Retro Biosciences is focused on extending the human lifespan.
News recently came out that it’s been working with OpenAI for a year on developing an AI model for longevity science.
The result is GPT-4b micro, which supports protein engineering and highlights OpenAI’s push into the life sciences realm, per ChatCBI.
Retro has been on OpenAI’s, particularly CEO Sam Altman’s, radar for some time now — Altman personally provided the startup with $180M back in 2022. You say conflict of interest? We say alignment of interests.
And it’s not new to us either — we covered the startup last year while mapping out the longevity tech landscape. Check out the market map here.
Not: GenAI adoption barriers
Security remains the dominant concern for strategy teams implementing genAI.
Nearly 46% of strategy leaders we surveyed cite security and privacy risks as a significant barrier to their organization’s adoption of genAI. Competing internal priorities (42%) and regulatory concerns (40%) follow close behind.
Technical challenges — such as development costs and talent shortages — rank notably lower, underlining the dominance of organizational and strategic obstacles.
This week, OpenAI and SoftBank announced a joint venture dubbed Stargate to build $500B of AI infrastructure in the US.
This level of spend is creating opportunities across the AI data center value chain, from energy providers (like nuclear) to support infrastructure (like cooling).
OpenAI included in its announcement a call for “firms across the built data center infrastructure landscape.”
